June 24, 2024
Human Microbiome Market

Global Human Microbiome Market Is Estimated To Witness High Growth Owing To Growing Demand for Precision Medicine and Increasing Investments in Microbiome Research

The global human microbiome market is estimated to be valued at US$115.42 million in 2021 and is expected to exhibit a CAGR of 31.08% over the forecast period 2021-2030.


A) Market Overview:

The human microbiome refers to the collection of microbes, including bacteria, viruses, fungi, and other microorganisms, that live in and on the human body. These microorganisms play a vital role in maintaining overall health and well-being. The human microbiome market includes various products and therapies aimed at modulating the microbial composition to promote better health outcomes.

The use cases of products associated with the human microbiome market are diverse and include precision medicine, diagnosis and treatment of various diseases, such as inflammatory bowel disease (IBD) and metabolic disorders, and boosting the immune system to prevent infections.


B) Market Dynamics:

The Human Microbiome Market is driven by two key factors: the growing demand for precision medicine and increasing investments in microbiome research.


Precision medicine focuses on individualizing healthcare by considering an individual’s genetic makeup, environment, and lifestyle. The human microbiome plays a crucial role in precision medicine as it influences drug metabolism, response to treatment, and susceptibility to certain diseases. As a result, there is a rising demand for microbiome-based diagnostics and therapeutics to tailor treatments according to an individual’s specific microbiome profile.


Furthermore, there has been a significant increase in investments in microbiome research. Both private and public organizations are funding research projects to explore the potential applications of the human microbiome in various therapeutic areas. For instance, Second Genome Therapeutics received $43 million in Series B funding to advance its microbiome-based drug discovery platform.


C) Market key trends:

One key trend in the human microbiome market is the growing interest in fecal microbiota transplantation (FMT). FMT involves transferring fecal material from a healthy donor into the gastrointestinal tract of a recipient to restore the microbial balance. This procedure has shown promising results in the treatment of recurrent Clostridium difficile infection and holds potential in addressing other diseases, such as inflammatory bowel disease and metabolic disorders.


An example of FMT’s effectiveness can be seen in the success of Rebiotix Inc. The company developed a microbiota restoration therapy called RBX2660, which demonstrated a 87.1% clinical cure rate in patients with recurrent C. difficile infection.


D) SWOT Analysis:


Increasing awareness about the importance of the human microbiome for overall health.

Growing research and development activities in the field of microbiome-based therapies.


Lack of personalized microbiome-based treatments.

Limited understanding of the complex interactions within the human microbiome.


Emerging applications of the human microbiome in areas such as oncology and neurology.

Collaborations between pharmaceutical companies and microbiome research organizations.


Regulatory challenges associated with microbiome-based therapies.

Competitive landscape with the presence of established market players.

E) Key Takeaways:

The global human microbiome market is expected to witness high growth, exhibiting a CAGR of 31.08% over the forecast period, due to the increasing demand for precision medicine and investments in microbiome research.

North America is projected to be the fastest-growing and dominating region in the human microbiome market. This can be attributed to the presence of key players, well-established healthcare infrastructure, and significant investments in research and development activities.

Key players operating in the global human microbiome market include ENTEROME SA, Embion Technologies S.A, IGEN BIOLAB GROUP, Evelo Biosciences Inc., Ferring Pharmaceuticals, 4D Pharma Plc., Gnubiotics Sciences, YSOPIA Bioscience, ViThera Pharmaceuticals Inc., SECOND GENOME THERAPEUTICS, Osel Inc., OxThera AB, Immuron Ltd., AOBiome, Vedanta Biosciences, Inc., Rebiotix Inc., Seres Therapeutics, Inc